Sugi Predict

Sugi Predict / Targets / CHAT

CHAT

Choline O-acetyltransferase · P28329 · CHAT on Sugi Atlas →

16,000 patent compounds predicted against CHAT, 9,632 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL300426 SCHEMBL300426 0.61 7/20
SCHEMBL372527 SCHEMBL372527 0.61 7/20
SCHEMBL132659 SCHEMBL132659 0.55 7/20
SCHEMBL272577 SCHEMBL272577 0.55 6/20
SCHEMBL612947 SCHEMBL612947 0.55 6/20
SCHEMBL422596 SCHEMBL422596 0.50 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL541687) 0.50 6/20
SCHEMBL889824 SCHEMBL889824 0.50 6/20
SCHEMBL318014 SCHEMBL318014 0.49 6/20
SCHEMBL318015 SCHEMBL318015 0.49 6/20
SCHEMBL873129 SCHEMBL873129 0.47 6/20
SCHEMBL873130 SCHEMBL873130 0.47 6/20
SCHEMBL87968 SCHEMBL87968 0.50 5/20
Bromide Bromide (SCHEMBL366167) 0.50 5/20
SCHEMBL615455 SCHEMBL615455 0.50 5/20
SCHEMBL615456 SCHEMBL615456 0.50 5/20
SCHEMBL490083 SCHEMBL490083 0.47 5/20
SCHEMBL490085 SCHEMBL490085 0.47 5/20
SCHEMBL531162 SCHEMBL531162 0.47 5/20
SCHEMBL658342 SCHEMBL658342 0.37 5/20

Clinical trials — most relevant to CHAT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) PHASE4UNKNOWN
Treatment of Tardive Dyskinesia With Galantamine PHASE4COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Detecting an Early Response to Donepezil With Measures of Visual Attention PHASE4COMPLETED
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease PHASE3COMPLETED
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome PHASE3UNKNOWN
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis PHASE2/PHASE3NOT_YET_RECRUITING
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition PHASE2RECRUITING
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism PHASE1/PHASE2COMPLETED
Nefiracetam in the Treatment of Alzheimer's Disease PHASE2COMPLETED
Donepezil Trial for Motor Recovery in Acute Stroke PHASE1/PHASE2WITHDRAWN
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics PHASE2WITHDRAWN
Gene Therapy for Alzheimer's Disease Clinical Trial PHASE1COMPLETED
The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease PHASE1COMPLETED
Multiple Ascending Dose Putative Cognitive Enhancer VU319 PHASE1WITHDRAWN
Bisnorcymserine in Healthy Adult Volunteers PHASE1COMPLETED
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development PHASE1RECRUITING
Development of Cognitive Assessment Tools in Parkinson Disease EARLY_PHASE1COMPLETED
Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain EARLY_PHASE1COMPLETED
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol nanUNKNOWN
Choline to Improve Malnutrition and Enhance Cognition nanRECRUITING
Supplemental Choline and Brain Development in Humans nanCOMPLETED
Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies nanCOMPLETED
Maternal Choline Supplementation and Offspring Cognition in Adolescence nanENROLLING_BY_INVITATION
The Dutch Parkinson and Cognition Study nanUNKNOWN
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome. nanRECRUITING
Cholinergic Markers Alzheimer's Disease nanCOMPLETED
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) nanACTIVE_NOT_RECRUITING
Cerebrovascular Changes in Multiple Sclerosis Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CHAT binder may also engage these)

ProteinNameSimilarity
Q03059 — 0.994 Q03059 →
Q8TCG5 — 0.991 Q8TCG5 →
P32738 — 0.988 P32738 →
Q63704 — 0.987 Q63704 →
Q90YJ9 — 0.987 Q90YJ9 →
Q924X2 — 0.985 Q924X2 →
F1LN46 — 0.982 F1LN46 →
Q8BGD5 — 0.982 Q8BGD5 →
B2ZGJ1 — 0.982 B2ZGJ1 →
CRAT Carnitine O-acetyltransferase 0.981 landscape →
P13222 — 0.981 P13222 →
P07668 — 0.979 P07668 →
Q704S8 — 0.979 Q704S8 →
P32198 — 0.979 P32198 →
Q8HY46 — 0.979 Q8HY46 →
CPT1B Carnitine O-palmitoyltransferase 1, muscle isoform 0.977 landscape →
P11466 — 0.977 P11466 →
P19113 — 0.977 P19113 →
KDM1A Lysine-specific histone demethylase 1A 0.976 landscape →
Q58DK1 — 0.976 Q58DK1 →
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform 0.976 landscape →
Q3TZX8 — 0.975 Q3TZX8 →
Q922B1 — 0.975 Q922B1 →
KDM5D Lysine-specific demethylase 5D 0.973 landscape →
NR1H2 Oxysterols receptor LXR-beta 0.973 landscape →
Q6ZQ88 — 0.973 Q6ZQ88 →
P97742 — 0.973 P97742 →
Q8K337 — 0.973 Q8K337 →
Q68Y62 — 0.972 Q68Y62 →
Q8K2J9 — 0.972 Q8K2J9 →